SCHEMBL6348703

SCHEMBL6348703

CON(C)C(=O)c1ccc(Oc2ccc(OCc3ccccc3)cc2C)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
PABPC1 P11940 1/20 0.41
FFAR1 O14842 2/20 0.41
MAOB P27338 1/20 0.41
EGFR P00533 3/20 0.41
APP P05067 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 1/20 0.40
RECQL P46063 1/20 0.40
NR4A1 P22736 1/20 0.40
NR4A2 P43354 1/20 0.40
NR4A3 Q92570 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
GCK P35557 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6338944 0.92 FFAR4 (0.43) PPARGPPARDKMT2AFFAR1APP
SCHEMBL6337027 0.87 ACACB (0.50) KMT2AMEN1PABPC1MAOBEGFR
SCHEMBL6337213 0.87 NR4A2 (0.52) PPARGPPARDKMT2AMEN1FFAR1
SCHEMBL6341086 0.86 MEN1 (0.47) PPARGPPARDKMT2AMEN1PABPC1
SCHEMBL6337233 0.86 MAOB (0.55) PPARGPPARDFFAR1MAOBLMNA
SCHEMBL31081572 0.82 CXCR2 (0.50) KMT2AMEN1PABPC1FFAR1MAOB
SCHEMBL6349045 0.79 PPARD (0.49) PPARGPPARDKMT2AMEN1PABPC1
SCHEMBL6348828 0.78 GRM2 (0.54) FFAR1NR4A1NR4A2NR4A3OPRM1
SCHEMBL6341725 0.78 OPRM1 (0.47) KMT2AMEN1PABPC1FFAR1TDP1
SCHEMBL6416751 0.77 MAOB (0.52) PPARGPPARDFFAR1MAOBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 PPARG 706/4885PPARD 1257/4885KMT2A 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.